By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Biomarkers Are Revolutionizing Breast Cancer Treatment Monitoring – Here’s How
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Specialties > Cancer > Biomarkers Are Revolutionizing Breast Cancer Treatment Monitoring – Here’s How
Cancer

Biomarkers Are Revolutionizing Breast Cancer Treatment Monitoring – Here’s How

Holly Hosler
Holly Hosler
Share
6 Min Read
Biomarkers are revolutionizing breast cancer treatment
SHARE

Biomarkers have revolutionized breast cancer treatment monitoring, ushering in a new era of approaches and methods. These remarkable biological indicators offer invaluable insights into the progression of diseases, the response to treatments, and the classification of patients.

Contents
  • What are biomarkers?
  • Breast cancer treatment monitoring with biomarkers
  • How biomarkers are revolutionizing breast cancer treatment monitoring
  • The outlook of biomarkers

In this article, we will delve into the significance of biomarkers in clinical research, explore the diverse types of biomarkers utilized in trials, and elucidate their crucial role in selecting and classifying patients.

What are biomarkers?

Biomarkers, in simple terms, are measurable biological characteristics that can be objectively evaluated and quantified. They provide essential information about the physiological state of an individual, such as the presence of a disease, its severity, and the response to a specific treatment. By analyzing biomarkers, clinicians and researchers gain deeper insights into the underlying mechanisms of diseases, paving the way for more targeted and effective interventions.

Breast cancer treatment monitoring with biomarkers

In the context of breast cancer, where disease develops with the uncontrolled growth and proliferation of cancer cells, the biomarkers that monitor the disease’s development include CA15-3, CA27.29, and thymidine kinase activity.

More Read

prostate cancer
Best hospitals for prostate cancer treatment
Men Can Develop Breast Cancer Too: What to Watch Out For
When Is a Mammogram Not a Mammogram?
Can Your Organization Pioneer a Fundraising and Wellness Campaign, Reaching More Than 1.7 Million Viewers?
Social Media Networking and Breast Cancer Awareness

CA15-3 stands for Cancer Antigen 15-3. It is a protein found in normal breast cells and elevated in the blood in some people with invasive breast cancer.This is not because it causes cancer – rather, it is shed by the tumor cells that enter the blood. It can be done with a blood sample drawn from the vein of the patient’s arm.

CA27.29 stands for Cancer Antigen 27.29. It is a high molecular weight glycoprotein, and alongside CA 15-3, it is a marker for breast cancer, albeit one that is not as sensitive. While results of CA27.29 tests are generally concordant with those of CA15-3 tests, they should not be interpreted interchangeably.

Thymidine kinase – particularly its isozyme thymidine kinase 1 – is another key biomarker for breast cancer. As a newer and less well-studied biomarker, TK1 activity levels in the blood of breast cancer patients can provide some insight into the development of the disease because of TK1’s role in cell proliferation. Particularly, TK1 is essential in the cell cycle, and as breast cancer develops, measuring TK1 activity levels can provide information on the speed at which cells are dividing. For example, decreasing TK1 activity in the blood samples of patients can have the potential to be an indicator related to the effectiveness of treatment therapies. Lower TK1 activity may also be correlated with lower aggression of the cancer in certain cases.

By regularly measuring and analyzing these biomarkers – namely their activity levels – with the use of tumor marker tests, clinicians can track the course of the disease and evaluate its response to specific treatments. It is a dynamic approach that is made accessible as biomarker testing can sometimes be done with a simple blood test, but these tests should not be done in isolation for the most precise monitoring of disease progression.

How biomarkers are revolutionizing breast cancer treatment monitoring

Biomarkers can be used as a monitoring tool during breast cancer treatment, and they can provide valuable insights in the development of the disease as well as the effectiveness of therapies. Their most revolutionary feature is how accessible testing is – which can be done with a sample of blood from patients. Testing can be easily incorporated into regular check-ups at lower costs compared to standard screening procedures. As part of blood tests, these biomarkers are also easy to obtain, allowing patients to avoid invasive procedures such as tissue biopsies.

Aside from working with end users, the use of biomarker testing can also produce new insights for researchers and clinicians when it comes to treatment development. Biomarkers can help them identify surrogate endpoints, providing a more practical way to access treatment outcomes and courses of treatment. With more data, researchers can potentially streamline the evaluation process and expedite the development of new therapies and solutions.

While biomarkers present valuable information about the development of breast cancer throughout treatment, clinicians use them with other monitoring methods to ensure they get a comprehensive view of the situation. This is because breast cancer is a multifaceted and complex disease, and the use of other screening tools (such as mammography) and clinical examinations can minimize knowledge gaps. Histopathological analysis of biopsy samples also remains a cornerstone in breast cancer disease monitoring.

The outlook of biomarkers

The future of biomarker usage and testing in breast cancer monitoring is highly promising. With ongoing research and technological advancements, clinicians and researchers can continue to expand their knowledge of how these biomarkers function, their correlation with the treatment effectiveness, and identify areas for further investigation. All this can lead to realizing the full potential of these biomarkers – and new ones yet to be uncovered – to improve patient outcomes in the years to come.

TAGGED:breast cancerBreast cancer screeningbreast cancer webinar
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

a woman walking on the hallway
6 Easy Healthcare Ways to Sit Less and Move More Every Day
Health
September 9, 2025
Clinical Expertise
Healthcare at a Crossroads: Why Leadership Matters More Than Ever
Global Healthcare
September 9, 2025
travel nurse in north carolina
Balancing Speed and Scope: Choosing the Nursing Degree That Fits Your Goals
Nursing
September 1, 2025
intimacy
How to Keep Intimacy Comfortable as You Age
Relationship and Lifestyle Senior Care
September 1, 2025

You Might also Like

Medical InnovationsSpecialtiesTechnology

New Advances Improve Breast Cancer Diagnosis And Treatment

February 1, 2018
breast cancer testing
DiagnosticsSpecialties

Angelina Jolie’s Decision: Do I Need to Be Tested?

May 21, 2013
cigna
BusinessHealth ReformMedical EthicsNewsPolicy & Law

Cigna’s Decision on Genetic Testing Exposes Educational Gaps in Today’s Healthcare

August 21, 2013

October is Breast Cancer Awareness Month

September 30, 2012
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?